Pharmaniaga Berhad Announces Major Share Consolidation: Key Details for Investors

Pharmaniaga Berhad (Bursa: 7081) has issued a comprehensive circular to its shareholders announcing a major capital restructuring exercise involving the consolidation of its shares. This initiative comes on the heels of the company’s successful exit from PN17 status, marking a significant milestone in its corporate journey.

Key Proposal: 5-to-1 Share Consolidation

• Proposed Share Consolidation: Pharmaniaga plans to consolidate every 5 existing ordinary shares into 1 new consolidated share. The entitlement date for determining shareholders’ eligibility will be announced at a later stage.
• Shareholder Meeting: The Extraordinary General Meeting (EGM) to approve this proposal is scheduled for Tuesday, 19 May 2026, at 2:00 p.m. The meeting will be held at Royale Ballroom, Royale Chulan Damansara, Petaling Jaya, Malaysia.
• Proxy Voting: Shareholders unable to attend can submit their proxy forms by 2:00 p.m. on Sunday, 17 May 2026. Proxy forms can be lodged physically or electronically.

Rationale Behind the Share Consolidation

• Post-PN17 Regularisation: Pharmaniaga recently received approval for the upliftment from PN17 status, effective 17 March 2026. The share consolidation is part of its strategy to enhance capital structure following this significant regulatory milestone.
• Market Impact: The consolidation will reduce the number of shares in the market, potentially resulting in a higher theoretical share price and lower price volatility. For example, based on the last closing price of RM0.245, the reference price post-consolidation would be RM1.225.
• Financial Metrics Enhancement: With fewer shares in issue, the company’s net assets per share (NA) and earnings per share (EPS) will increase, reflecting a more robust financial standing.

Detailed Effects of the Share Consolidation

• Issued Shares: The consolidation will reduce Pharmaniaga’s issued shares from 6,557,025,388 to 1,311,405,077 (minimum scenario) or from 6,598,180,348 to 1,319,636,069 (maximum scenario, assuming all outstanding share options are exercised).
• Share Capital: The RM value of the issued share capital remains unchanged, ensuring no dilution of value for shareholders.
• EPS and NA: EPS will jump from 1.34 sen to 6.69 sen (minimum scenario), while NA per share will increase from RM0.07 to RM0.33 (minimum scenario), with gearing ratios unaffected.
• Convertible Securities: The company has 41,154,960 outstanding share options, but the consolidation will occur after their expiry, so no adjustment is expected.
• Substantial Shareholders: The percentage of shareholdings of major shareholders, such as Boustead Holdings Berhad, Jakel Medical Sdn Bhd, and Lembaga Tabung Angkatan Tentera, remains unchanged, but their absolute number of shares will reduce proportionally.

Important Shareholder Information

• Price-Sensitive Aspects:
  • The consolidation reduces the number of shares, which typically leads to a higher market price per share, potentially attracting new investors and reducing speculative trading.
  • Fractional entitlements arising from the consolidation will be disregarded and handled at the Board’s discretion, which could affect shareholders with odd-lot holdings.
  • The consolidation does not impact the proportionate ownership of existing shareholders.
• Approvals Required:
  • Bursa Securities has approved the proposal, subject to compliance with regulatory requirements.
  • Shareholders’ approval at the EGM is required.
  • Consent from the company’s financiers for the share capital structure alteration is also necessary.
• Timeline:
  • EGM on 19 May 2026
  • Entitlement date announcement and implementation in early June 2026, with new consolidated shares listed shortly thereafter.
• No Other Pending Corporate Exercises: The Board confirms that there are no other pending corporate exercises apart from this proposed share consolidation.
• Directors’ Recommendation: The Board unanimously recommends that shareholders vote in favour of the proposal, citing it as being in the best interest of the company.

Risks and Considerations

• Share Price Volatility: While the consolidation aims to reduce volatility, there may be short-term market reactions as investors adjust to the new share structure and price.
• Odd Lots: Shareholders with holdings not in multiples of five may end up with odd lots after the consolidation, which are typically less liquid.
• Corporate Governance: All major approvals have been or are expected to be obtained, and the process is conducted under strict regulatory compliance.

Conclusion

Pharmaniaga’s proposed 5-to-1 share consolidation is a significant corporate action that could positively impact the company’s market perception, financial metrics, and share price stability. As the company emerges from PN17 status and seeks to normalise its capital structure, this action is positioned as a strong step towards future growth and value creation for shareholders.

Shareholders are strongly encouraged to review the full circular, consider the implications carefully, and participate in the upcoming EGM, either in person or by proxy.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should read the full circular and consult with their financial advisors before making any investment decisions. The information is based on official company documents and may be subject to change pending regulatory or shareholder approval.

View PHARMANIAGA BERHAD Historical chart here